BioNexus Gene Lab Corp. Real Estate Owned, Valuation Allowance, Valuation Increase
BioNexus Gene Lab Corp. (BGLC) reported Real Estate Owned, Valuation Allowance, Valuation Increase of $12.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Banking and Thrift
us-gaap:RealEstateOwnedValuationAllowanceValuationIncrease · last filed 2026-08-14
- BioNexus Gene Lab Corp. real estate owned, valuation allowance, valuation increase for the quarter ending 2026-06-30 was -$87.33K.
- BioNexus Gene Lab Corp. real estate owned, valuation allowance, valuation increase for the quarter ending 2026-03-31 was $12.16M.
- BioNexus Gene Lab Corp. real estate owned, valuation allowance, valuation increase for fiscal 2025 was $11.61M.
| Period end | Real Estate Owned, Valuation Allowance, Valuation Increase 3 month | Real Estate Owned, Valuation Allowance, Valuation Increase 6 month | Real Estate Owned, Valuation Allowance, Valuation Increase 12 month |
|---|---|---|---|
| 2026-06-30 | -$87.33K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $12.07M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $12.16M 10-Q · filed 2026-05-15 | ||
| 2025-12-31 | $11.61M 10-K · filed 2026-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |